ethyl 2-(((benzyloxy)carbonyl)amino)-3,3,3-trifluoro-2-hydroxypropanoate | 126535-86-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-(((benzyloxy)carbonyl)amino)-3,3,3-trifluoro-2-hydroxypropanoate
• 英文别名: Ethyl 2-(benzyloxycarbonylamino)-3,3,3-trifluoro-2-hydroxypropanoate；ethyl 3,3,3-trifluoro-2-hydroxy-2-(phenylmethoxycarbonylamino)propanoate
• CAS: 126535-86-2
• 化学式: C₁₃H₁₄F₃NO₅
• 分子量: 321.253
• InChiKey: BDAPKGFGWZUNEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  ethyl 2-(((benzyloxy)carbonyl)amino)-3,3,3-trifluoro-2-hydroxypropanoate 在 吡啶 、 三氟乙酸酐 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 ethyl 2-[[(2R)-2-(1,3-dioxoisoindol-2-yl)-3-phenylpropanoyl]amino]-3-methyl-2-(trifluoromethyl)butanoate
  参考文献：
  名称：

  Incorporation of the Unusual C^α-Fluoroalkylamino Acids into Cyclopeptides:  Synthesis of Arginine−Glycine−Aspartate (RGD) Analogues and Study of Their Conformational and Biological Behavior

  摘要：

  A series of six arginine-glycine-aspartate (RGD) cyclopeptide analogues containing a C-alpha-di- or trifluoromethylamino acid (alpha-Dfm or alpha-TfmAaa) at different positions of the ring were synthesized. All peptides were obtained in two diastereomeric forms, which were separated by HPLC. In vitro biological tests of the new cyclopeptides P were carried out in comparison with their corresponding cyclopeptides R lacking the alpha-fluoromethyl group. Five out of the six compounds P-I (containing (S)-alpha-Tfm-Aaa) showed activities in the nanomolar range, while the P-II compounds (containing (R)-a-Tfm-Aaa) were much less active or totally inactive. Only cyclo[RGDf-(S)-alpha TfmV] (P1-I) was found to be significantly more active than its model compound cyclo(RGDfV) (R1). The three-dimensional structure in water and DMSO was determined by NMR techniques and molecular dynamics (MD) calculations, but it was not possible to highlight significant differences in the backbone conformation of the peptides examined. Significant interproton distances, derived from nuclear Overhauser effect (NOE) experiments, were used to determine the absolute configuration of the side chains.

  DOI：

  10.1021/jm0511334
• 作为产物：
  描述：

  ethyl 2-(((benzyloxy)carbonyl)amino)-2-chloro-3,3,3-trifluoropropanoate 在 silver carbonate 作用下， 以 氘代氯仿 为溶剂， 反应 24.0h， 生成 ethyl 2-(((benzyloxy)carbonyl)amino)-3,3,3-trifluoro-2-hydroxypropanoate
  参考文献：
  名称：

  Aza-Friedel-Crafts 烷基化的广泛底物范围，用于合成四元 α-氨基酯。

  摘要：

  已经开发了一种用于合成季 α-氨基酯的 aza-Friedel-Crafts 烷基化的通用合成方案。这种操作简单的烷基化在环境条件下以高效率、区域选择性和极其广泛的芳烃亲核试剂进行。这种烷基化的一个关键特征是与反应过程中释放的银 (I) 盐抗衡阴离子相关的作用。利用相转移反阴离子/布朗斯台德酸对机制，我们还报告了该反应的催化对映选择性示例。

  DOI：

  10.1021/acs.orglett.0c01895

文献信息

• [EN] 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE LA RATE (SYK) CONTENANT UN 3-PYRIDYL CARBOXAMIDE
  申请人：MERCK SHARP & DOHME

  公开号：WO2013052393A1

  公开（公告）日：2013-04-11

  The invention provides certain 3-pyridyl carboxamide-containing compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  这项发明提供了具有以下结构的某些含有3-吡啶基羧酰胺的化合物的公式（I）（I）或其药用盐，其中A和B如本文所定义。该发明还提供了包括这些化合物的药物组合物，以及利用这些化合物治疗由脾酪氨酸激酶（Syk）激酶介导的疾病或症状的方法。
• Mechanistic Studies and Expansion of the Substrate Scope of Direct Enantioselective Alkynylation of α-Ketiminoesters Catalyzed by Adaptable (Phebox)Rhodium(III) Complexes
  作者：Kazuhiro Morisaki、Masanao Sawa、Ryohei Yonesaki、Hiroyuki Morimoto、Kazushi Mashima、Takashi Ohshima

  DOI：10.1021/jacs.6b01590

  日期：2016.5.18

  Mechanistic studies and expansion of the substrate scope of direct enantioselective alkynylation of α-ketiminoesters catalyzed by adaptable (phebox)rhodium(III) complexes are described. The mechanistic studies revealed that less acidic alkyne rather than more acidic acetic acid acted as a proton source in the catalytic cycle, and the generation of more active (acetato-κ(2)O,O')(alkynyl)(phebox)rhodium(III)

  描述了由适应性 (phebox) 铑 (III) 配合物催化的 α-酮亚氨基酯直接对映选择性炔基化的机理研究和底物范围的扩展。机理研究表明，酸性较低的炔烃而不是酸性较高的乙酸在催化循环中充当质子源，并且生成更活跃的（乙酰基-κ（2）O，O'）（炔基）（苯甲酸）铑（ III) 来自起始（二乙酸根）铑（III）配合物的配合物限制了反应的整体反应性。这些发现，以及（炔基）铑（III）配合物上炔基配体的轻松交换导致我们使用（乙酰基-κ（2）O，O'）（三甲基甲硅烷基乙炔基）（phebox）铑（III）配合物作为各种（炔基）铑（III）配合物的通用预催化剂。
• [EN] TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE TRIPEPTIDE ÉPOXY CÉTONE PROTÉASE
  申请人：ONYX THERAPEUTICS INC

  公开号：WO2014152134A1

  公开（公告）日：2014-09-25

  Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.

  本文提供了三肽环氧酮蛋白酶抑制剂，它们的制备方法，相关的药物组合物，以及使用它们的方法。例如，本文提供了式（X）的化合物：以及包括它们的药物可接受的盐和组合物。本文提供的化合物和组合物可以用于治疗炎症和神经退行性疾病等疾病。
• 3-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors
  申请人：MERCH SHARP & DOHME CORP.

  公开号：US20140303206A1

  公开（公告）日：2014-10-09

  The invention provides certain 3-pyridyl carboxamide-containing compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  本发明提供了一些含有3-吡啶基羧酰胺的化合物，其化学式为(I)或其药学上可接受的盐，其中A和B的定义如本文所述。本发明还提供了包含这些化合物的制药组合物，并使用这些化合物治疗由脾酪氨酸激酶(Syk)介导的疾病或病况的方法。
• TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS
  申请人：Onyx Therapeutics, Inc.

  公开号：US20140336106A1

  公开（公告）日：2014-11-13

  Provided herein are tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of diseases including inflammation and neurodegenerative disease.

  本文提供了三肽环氧酮蛋白酶抑制剂及其制备方法、相关药物组合物和使用方法。例如，本文提供了式（X）的化合物及其药物可接受的盐和组合物。本文提供的化合物和组合物可以用于治疗包括炎症和神经退行性疾病在内的疾病。